116 related articles for article (PubMed ID: 38479443)
1. A population-based analysis of the impact of 1 vs. 2 doses of mitomycin on patterns of failure of anal cancer patients treated with concurrent chemoradiotherapy.
Joseph K; Al Habsi Z; Abraham A; Elangovan A; Ghosh S; Pham T; Shreekumar D; Ramji Z; Paulson K; Tankel K; Usmani N; Severin D; Schiller D; Wong C; Mulder K; Karachiwala H; Doll C; King K; Nijjar T
Radiother Oncol; 2024 Jul; 196():110219. PubMed ID: 38479443
[TBL] [Abstract][Full Text] [Related]
2. Chemoradiotherapy for squamous cell carcinoma of the anal canal: Comparison of one versus two cycles mitomycin-C.
White EC; Goldman K; Aleshin A; Lien WW; Rao AR
Radiother Oncol; 2015 Nov; 117(2):240-5. PubMed ID: 26347494
[TBL] [Abstract][Full Text] [Related]
3. Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin.
Gunderson LL; Winter KA; Ajani JA; Pedersen JE; Moughan J; Benson AB; Thomas CR; Mayer RJ; Haddock MG; Rich TA; Willett CG
J Clin Oncol; 2012 Dec; 30(35):4344-51. PubMed ID: 23150707
[TBL] [Abstract][Full Text] [Related]
4. Toxicity, Tolerability, and Compliance of Concurrent Capecitabine or 5-Fluorouracil in Radical Management of Anal Cancer With Single-dose Mitomycin-C and Intensity Modulated Radiation Therapy: Evaluation of a National Cohort.
Jones CM; Adams R; Downing A; Glynne-Jones R; Harrison M; Hawkins M; Sebag-Montefiore D; Gilbert DC; Muirhead R
Int J Radiat Oncol Biol Phys; 2018 Aug; 101(5):1202-1211. PubMed ID: 29859793
[TBL] [Abstract][Full Text] [Related]
5. Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial.
Gunderson LL; Moughan J; Ajani JA; Pedersen JE; Winter KA; Benson AB; Thomas CR; Mayer RJ; Haddock MG; Rich TA; Willett CG
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):638-45. PubMed ID: 24035327
[TBL] [Abstract][Full Text] [Related]
6. Three cytotoxic drugs combined with pelvic radiation and as maintenance chemotherapy for patients with squamous cell carcinoma of the anus (SCCA): long-term follow-up of a phase II pilot study using 5-fluorouracil, mitomycin C and cisplatin.
Sebag-Montefiore D; Meadows HM; Cunningham D; Plowman PN; Hurman DC; Davidson N; Grieve R; Levine E; Glynne-Jones R
Radiother Oncol; 2012 Aug; 104(2):155-60. PubMed ID: 22857859
[TBL] [Abstract][Full Text] [Related]
7. Capecitabine With Mitomycin Reduces Acute Hematologic Toxicity and Treatment Delays in Patients Undergoing Definitive Chemoradiation Using Intensity Modulated Radiation Therapy for Anal Cancer.
Goodman KA; Julie D; Cercek A; Cambridge L; Woo KM; Zhang Z; Wu AJ; Reidy DL; Segal NH; Stadler ZK; Saltz LB
Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1087-1095. PubMed ID: 28721892
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive treatment experience of anal squamous cell carcinoma from a tertiary cancer center in South China.
Yuan Y; Xie WH; Li RZ; Chang H; Zeng ZF; Gao YH; Wang QX; Xiao WW
Cancer Med; 2022 Jan; 11(1):117-127. PubMed ID: 34816622
[TBL] [Abstract][Full Text] [Related]
9. Pencil Beam Scanning Proton Beam Chemoradiation Therapy With 5-Fluorouracil and Mitomycin-C for Definitive Treatment of Carcinoma of the Anal Canal: A Multi-institutional Pilot Feasibility Study.
Wo JY; Plastaras JP; Metz JM; Jiang W; Yeap BY; Drapek LC; Adams J; Baglini C; Ryan DP; Murphy JE; Parikh AR; Allen JN; Clark JW; Blaszkowsky LS; DeLaney TF; Ben-Josef E; Hong TS
Int J Radiat Oncol Biol Phys; 2019 Sep; 105(1):90-95. PubMed ID: 31128146
[TBL] [Abstract][Full Text] [Related]
10. Feasibility and Outcome of Routine Use of Concurrent Chemoradiation in HIV-positive Patients With Squamous Cell Anal Cancer.
Leiker AJ; Wang CJ; Sanford NN; Aguilera TA; Karri S; Beg MS; Kazmi SA; Olson C; Matthews JA; Abdelnaby A; Meyer JJ; Folkert MR
Am J Clin Oncol; 2020 Oct; 43(10):701-708. PubMed ID: 32694298
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of prognostic factors after primary chemoradiotherapy of anal cancer: A multicenter study of the German Cancer Consortium-Radiation Oncology Group (DKTK-ROG).
Martin D; Schreckenbach T; Ziegler P; Filmann N; Kalinauskaite G; Tinhofer I; Budach V; Gani C; Zips D; Schimek-Jasch T; Schäfer H; Grosu AL; Thomas E; Krause M; Dapper H; Combs S; Hoffmann C; Stuschke M; Walter F; Belka C; Kurth I; Hadiwikarta WW; Baumann M; Rödel C; Fokas E
Radiother Oncol; 2022 Feb; 167():233-238. PubMed ID: 34999135
[TBL] [Abstract][Full Text] [Related]
12. Twenty-five-year experience with radical chemoradiation for anal cancer.
Tomaszewski JM; Link E; Leong T; Heriot A; Vazquez M; Chander S; Chu J; Foo M; Lee MT; Lynch CA; Mackay J; Michael M; Tran P; Ngan SY
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):552-8. PubMed ID: 22019078
[TBL] [Abstract][Full Text] [Related]
13. One compared with two cycles of mitomycin C in chemoradiotherapy for anal cancer: analysis of outcomes and toxicity.
Yeung R; McConnell Y; Roxin G; Banerjee R; Urgoiti GB; MacLean AR; Buie WD; Mulder KE; Vickers MM; Joseph KJ; Doll CM
Curr Oncol; 2014 Jun; 21(3):e449-56. PubMed ID: 24940105
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer.
Leon O; Guren MG; Radu C; Gunnlaugsson A; Johnsson A
Eur J Cancer; 2015 Dec; 51(18):2740-6. PubMed ID: 26597443
[TBL] [Abstract][Full Text] [Related]
15. Phase II Study of Capecitabine in Substitution of 5-FU in the Chemoradiotherapy Regimen for Patients with Localized Squamous Cell Carcinoma of the Anal Canal.
Oliveira SC; Moniz CM; Riechelmann R; Alex AK; Braghirolli MI; Bariani G; Nahas C; Hoff PM
J Gastrointest Cancer; 2016 Mar; 47(1):75-81. PubMed ID: 26691173
[TBL] [Abstract][Full Text] [Related]
16. Chemoradiotherapy for anal cancer: are we as good as we think?
Martin D; Rödel C; Fokas E
Strahlenther Onkol; 2019 May; 195(5):369-373. PubMed ID: 30937508
[TBL] [Abstract][Full Text] [Related]
17. High IDO1 Expression Is Associated with Poor Outcome in Patients with Anal Cancer Treated with Definitive Chemoradiotherapy.
Mitra D; Horick NK; Brackett DG; Mouw KW; Hornick JL; Ferrone S; Hong TS; Mamon H; Clark JW; Parikh AR; Allen JN; Ryan DP; Ting DT; Deshpande V; Wo JY
Oncologist; 2019 Jun; 24(6):e275-e283. PubMed ID: 30755500
[TBL] [Abstract][Full Text] [Related]
18. Chemoradiotherapy of anal carcinoma: survival and recurrence in an unselected national cohort.
Bentzen AG; Guren MG; Wanderås EH; Frykholm G; Tveit KM; Wilsgaard T; Dahl O; Balteskard L
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):e173-80. PubMed ID: 22436791
[TBL] [Abstract][Full Text] [Related]
19. Tumour- and treatment-related colostomy rates following mitomycin C or cisplatin chemoradiation with or without maintenance chemotherapy in squamous cell carcinoma of the anus in the ACT II trial.
Glynne-Jones R; Kadalayil L; Meadows HM; Cunningham D; Samuel L; Geh JI; Lowdell C; James R; Beare S; Begum R; Ledermann JA; Sebag-Montefiore D;
Ann Oncol; 2014 Aug; 25(8):1616-22. PubMed ID: 24827136
[TBL] [Abstract][Full Text] [Related]
20. Primary surgery with or without postoperative radiotherapy in early stage squamous cell carcinoma in the anal canal and anal margin.
Leon O; Hagberg O; Johnsson A
Acta Oncol; 2018 Sep; 57(9):1209-1215. PubMed ID: 29490558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
